Necrotizing vasculitis
diseaseOn this page
Also known as systemic vasculitis
Summary
Necrotizing vasculitis (MONDO:0800113) is a disease and 17 clinical trials. Top therapeutic interventions include rituximab and varicella zoster virus envelope glycoprotein e. A subtype of vasculitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 17
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | necrotizing vasculitis |
| Mondo ID | MONDO:0800113 |
| NCIT | C70635 |
| UMLS | C1318520 |
| MedGen | 230813 |
| GARD | 0005106 |
| Is cancer (heuristic) | no |
Also known as: systemic vasculitis
Disease family
This is a subtype of vasculitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › vasculitis › necrotizing vasculitis
Related subtypes (17): choroiditis, Shwartzman phenomenon, central nervous system vasculitis, phlebitis, lymphangitis, aortitis, hypersensitivity vasculitis, retinal vasculitis, vasculitis, lymphocytic, nodular, Kawasaki disease, deficiency of adenosine deaminase 2, immune complex mediated vasculitis, secondary vasculitis, cutaneous vasculitis, livedoid vasculopathy, autoimmune vasculitis, arteritis
Subtypes (3): anti-neutrophil cytoplasmic antibody-associated vasculitis, immunoglobulin A vasculitis, disseminated visceral giant cell angiitis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 17.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 10 |
| PHASE4 | 3 |
| PHASE2 | 2 |
| PHASE3 | 1 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06763783 | PHASE4 | ENROLLING_BY_INVITATION | Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases |
| NCT01151644 | PHASE4 | UNKNOWN | Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases |
| NCT03762824 | PHASE4 | COMPLETED | Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease |
| NCT01257802 | PHASE3 | TERMINATED | GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases |
| NCT05236491 | PHASE2/PHASE3 | UNKNOWN | COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases |
| NCT02556866 | PHASE2 | TERMINATED | Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis |
| NCT03514979 | PHASE2 | UNKNOWN | Acquired Immunodeficiency in ANCA Associated Vasculitis |
| NCT02593565 | Not specified | RECRUITING | Vasculitis Pregnancy Registry |
| NCT06642870 | Not specified | RECRUITING | Rare AutoImmune SElf-management Programme Development |
| NCT07037732 | Not specified | RECRUITING | Circulating B-cell, Drug and Anti-drug Antibodies Monitoring in Patients Treated With Rituximab for Autoimmune Disorders |
| NCT01314547 | Not specified | COMPLETED | Impact of Environmental Factors on Disease Activity in Spondyloarthritis (SPA): Results of the Prospective Co-Env Cohort |
| NCT01599260 | Not specified | TERMINATED | Resistance Exercise in Rheumatic Disease |
| NCT02042092 | Not specified | COMPLETED | Magnetic Resonance Angiography vs Ultrasonography in Systemic Large vEssel vasculitiS |
| NCT02476292 | Not specified | COMPLETED | Impact of Vasculitis on Employment and Income |
| NCT03410290 | Not specified | COMPLETED | Journey of Patients With Vasculitis From First Symptom to Diagnosis |
| NCT03543527 | Not specified | UNKNOWN | Study of Refractory and/or Relapsing TAkayasu aRTeritis |
| NCT05164822 | Not specified | TERMINATED | Evolution of Neuropathies Associated With Necrotizing Vasculitis |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| RITUXIMAB | 4 | 1 |
| VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E | 4 | 1 |